ClinicalTrialsFinder

Relapsed/Refractory AL Amyloidosis Clinical Trials in Beijing

1 recruitingBeijing, China

Showing 1–1 of 1 trials

Recruiting
Phase 1

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Relapsed/Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd.9 enrolled9 locationsNCT07250269